EGFR T790M (Q25100112)

From Wikidata

Jump to navigation Jump to search

genetic variant

THR790MET
T790M
RS121434569

Language	Label	Description	Also known as
English	EGFR T790M	genetic variant	THR790MET T790M RS121434569

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

human chromosome 7

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

55249071

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

55249071

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

positive therapeutic predictor for

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/646

Rociletinib in EGFR-mutated non-small-cell lung cancer

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level E

CIViC 1-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/278

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/963

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/965

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/966

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/762

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

medical condition treated

adenocarcinoma of the lung

determination method or standard

CIViC evidence level C

CIViC 1-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1397

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

medical condition treated

adenocarcinoma of the lung

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2157

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2162

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

medical condition treated

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2165

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

pemetrexed / erlotinib combination therapy

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/277

Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/967

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/967

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2161

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

pancreatic adenocarcinoma

statement disputed by

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6006

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance

negative therapeutic predictor for

determination method or standard

CIViC evidence level A

CIViC 5-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/238

EGFR T790M resistance mutation in non small-cell lung carcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/240

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1391

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1391

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1667

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1863

Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.

determination method or standard

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2160

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

determination method or standard

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2158

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

determination method or standard

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2158

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

negative prognostic predictor for

non-small-cell lung carcinoma

determination method or standard

CIViC evidence level B

CIViC 4-star trust rating

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/369

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis

23 May 2022

https://civic.genome.wustl.edu/links/evidence/370

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

dbSNP Reference SNP number

1 reference

Google Knowledge Graph ID

0 references

HGVS nomenclature

ENST00000275493.2:c.2369C>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

NM_005228.4:c.2369C>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

NP_005219.2:p.Thr790Met

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

NC_000007.13:g.55249071C>T

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/34

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Sitelinks

Wikipedia(6 entries)

dewiki EGFR-Mutation T790M
enwiki T790M
fawiki T790M
frwiki T790M
viwiki T790M
zhwiki T790M

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q25100112&oldid=2014772074"